Comparison of Industry Payments in 2017 With Annual Salary in a Cohort of Academic Oncologists

Abstract

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.Disclaimer: Dr Bibbins-Domingo is the former chair of the US Preventive Services Task Force (USPSTF). This article reflects her own work and not the official positions of the USPSTF.

Industry payments to US physicians for cancer therapeutics: An analysis of the 2016–2018 open payments datasets

“…Although it is known that payments from industry may be substantial [23], this is the first study to quantify the number of physicians receiving "significant" (i.e. > $10 000) annual payments.…”

General payments from Biogen to U.S. physicians between 2015 and 2020

“…It is wellestablished that pharmaceutical companies provide financial incentives to medical professionals. [3][4][5][6] The Open Payments (OP) database was established to track industry payments as part of the Physician Payment Sunshine Act. Since its inception, numerous studies have explored payments across medical specialties, including linking these data with Medicare to demonstrate how even small sums can influence prescribing.…”

Industry payments to Australian medical oncologists and clinical haematologists: a cross‐sectional analysis of publicly available disclosures

“…In other jurisdictions, this has been explored in detail. In the United States, according to mandated industry disclosures, between 52.4% and 66.2% of oncologists receive direct funding 15–17 . In Japan, the rate is as high as 70.6% 18 .…”